Whether treatment with erythropoietin (EPO) is of benefit is the subject of several ongoing studies. Therapy with EPO does not increase hemoglobin levels in a considerable proportion of patients.

Despite its profound impact on patient health, anemia of chronic kidney disease (CKD) remains underdiagnosed and undertreated.

The global erythropoietin drugs market was valued at approximately USD 6.87 billion in 2022 and is projected to grow at a healthy growth rate of around 1.5% during the forecast period from 2023 to ...

The Ekosiisen Impact Project, an initiative under Asempa FM’s flagship current affairs programme Ekosiisen, has intensified its support for renal patients across Ghana, following a distress call from ...

Researchers are developing AI programmes to make doping detection more effective, faster, and cheaper. How do these systems ...

CHENNAI: Asian Games medallist in canoe, international medallists and quite a few minors are on the latest list of ...

An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient characteristics ...

In contrast to the recently reported studies of Epo in patients hospitalized in intensive care units focusing on those with trauma, [60] our study was designed to minimize the risk of Epo-induced ...

Erythropoietin reduces infarct size, but it also carries some potentially adverse affects. How can you effectively administer this drug to improve the prognosis of heart disease patients?

After being stripped of his seven Tour de France titles for doping, Lance Armstrong shouldn’t be allowed anywhere near ...

Las Vegas will play host to the Enhanced Games – a competition where doping is not just allowed, it's required. Behind the ...